PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

PCSK9 Inhibitors: Research & Evidence

Established Evidence

Published research, clinical trial data, and evidence grading for PCSK9 Inhibitors across studied indications.

Back to PCSK9 Inhibitors overview

Research Summary

PCSK9 inhibitors have the strongest evidence base of any compound class in this collection — 200+ human studies, 50+ RCTs, and 3 major cardiovascular outcomes trials (FOURIER with 27,564 patients, ODYSSEY OUTCOMES with 18,924 patients, and ORION trials with ~3,600 patients). All three agents are FDA-approved: alirocumab (Praluent, 2015), evolocumab (Repatha, 2015), and inclisiran (Leqvio, 2021). LDL-C reduction of 50-60% and 15% relative risk reduction in MACE are consistently demonstrated. Important note: these are NOT peptides — alirocumab and evolocumab are monoclonal antibodies, and inclisiran is an siRNA therapeutic. They are included as important agents in the PCSK9 lipid-lowering pathway.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
LDL cholesterol reduction Tier A 50 Consistent 50-60% LDL-C reduction across 50+ RCTs
Cardiovascular event prevention Tier A 3 FOURIER and ODYSSEY OUTCOMES demonstrated 15% MACE reduction
Familial hypercholesterolemia Tier A 10 FDA-approved indication with robust evidence

Graded using our evidence tier methodology.

Citations (4 sources)

  1. 1. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease Clinical Trial

    Sabatine MS, Giugliano RP, Keech AC, et al. (2017), New England Journal of Medicine

  2. 2. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome Clinical Trial

    Schwartz GG, Steg PG, Szarek M, et al. (2018), New England Journal of Medicine

  3. 3. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol Clinical Trial

    Ray KK, Wright RS, Kallend D, et al. (2020), New England Journal of Medicine

  4. 4. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events Clinical Trial

    Robinson JG, Farnier M, Krempf M, et al. (2015), New England Journal of Medicine